MSTN and rheumatoid arthritis: Our cohort study firstly investigated the relationships of serum myostatin and disease activity changes during one-year follow-up, and found higher disease activity indicators at 3, 6, and 9 months and lower rate of CDAI remission at 9 months in RA patients with high myostatin group, though no significant difference at baseline.